Posted by Michael Wonder on 15 Jul 2021
Merck’s MET inhibitor tepotinib gains positive opinion from MHRA
15 July 2021 - The UK MHRA has issued a positive scientific opinion for Merck’s tepotinib for the treatment of advanced non-small cell lung cancer with METex14 skipping alterations.
The positive opinion has been issued via the MHRA’s early access the medicine scheme, which aims to give patients access to medicines that do not yet have a marketing authorisation but where there ‘is a clear unmet medical need,.
